J&J strikes Alzheimer’s deal with AC Immune worth up to $509 million

January 12, 2015 10:11 AM

8 0

(Reuters) - Johnson & Johnson boosted its research efforts in Alzheimer's on Monday by striking a deal potentially worth up to $509 million with unlisted Swiss biotech firm AC Immune to develop so-called anti-tau vaccines.

Tau is a protein known for forming tangles inside brain cells and is linked to cell death. It is one of two abnormal proteins tied to the memory-robbing disease. The other is beta amyloid.

Read more

To category page